Jul 30, 2026Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Jul 28, 2026Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
Jul 1, 2026UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
Jun 11, 2026Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
May 28, 2026Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual MeetingPresentation / Abstract
May 27, 2026American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
May 20, 2026FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
May 7, 2026Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
May 4, 2026Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Apr 30, 2026Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
